[Study of viral replication in HbsAg positive chronic hepatitis]. 1991

J Tomás Gilabert, and M I Galán Navarro, and T Caballero Morales, and M C Maroto Vela, and A Ruiz Extremera, and F J Salmerón Escobar
Servicio de Microbiología, Hospital Universitario de Granada.

Viral replication seric markers (VRSM), (BeHAg, BcHAg, and DNA-VHB) and the hepatic tissue BcHAg of thirty four patients suffering from chronic hepatopathies (6 PCH, 18 ACH, and 10 cirrhosis) were investigated. The greatest incidence of RVSM was observed in PCH. The combined study using all the markers demonstrated a positive correlation: DNA-VHB and BeHAg (p less than 0,001); DNA-VHB and BcHAg (p less than 0,001); BeHAg and BcHAg (p less than 0,001). The same result was obtained when comparing BcHAg (n) with the rest of RVSM: DNA-VHB (p less than 0,001), BeHAg (p less than 0,001) and seric BcHAg (p less than 0,01). Patients with a most intense histologic activity according to the Knodell index, presented a higher ratio of positive nuclei for BcHAg. The conclusion is that there is a good correlation amongst replication markers, specially hepatic BcHAg and DNA-VHB.

UI MeSH Term Description Entries
D008107 Liver Diseases Pathological processes of the LIVER. Liver Dysfunction,Disease, Liver,Diseases, Liver,Dysfunction, Liver,Dysfunctions, Liver,Liver Disease,Liver Dysfunctions
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D006511 Hepatitis B Antigens Antigens of the virion of the HEPATITIS B VIRUS or the Dane particle, its surface (HEPATITIS B SURFACE ANTIGENS), core (HEPATITIS B CORE ANTIGENS), and other associated antigens, including the HEPATITIS B E ANTIGENS. HBAg,Hepatitis B Antigen,Antigen, Hepatitis B,Antigens, Hepatitis B,B Antigen, Hepatitis,B Antigens, Hepatitis
D006514 Hepatitis B Surface Antigens Those hepatitis B antigens found on the surface of the Dane particle and on the 20 nm spherical and tubular particles. Several subspecificities of the surface antigen are known. These were formerly called the Australia antigen. Australia Antigen,HBsAg,Hepatitis B Surface Antigen,Antigen, Australia
D006515 Hepatitis B virus The type species of the genus ORTHOHEPADNAVIRUS which causes human HEPATITIS B and is also apparently a causal agent in human HEPATOCELLULAR CARCINOMA. The Dane particle is an intact hepatitis virion, named after its discoverer. Non-infectious spherical and tubular particles are also seen in the serum. Dane Particle,Hepatitis Virus, Homologous Serum,B virus, Hepatitis,Hepatitis B viruses,Particle, Dane,viruses, Hepatitis B
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D014779 Virus Replication The process of intracellular viral multiplication, consisting of the synthesis of PROTEINS; NUCLEIC ACIDS; and sometimes LIPIDS, and their assembly into a new infectious particle. Viral Replication,Replication, Viral,Replication, Virus,Replications, Viral,Replications, Virus,Viral Replications,Virus Replications
D015415 Biomarkers Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, ENVIRONMENTAL EXPOSURE and its effects, disease diagnosis; METABOLIC PROCESSES; SUBSTANCE ABUSE; PREGNANCY; cell line development; EPIDEMIOLOGIC STUDIES; etc. Biochemical Markers,Biological Markers,Biomarker,Clinical Markers,Immunologic Markers,Laboratory Markers,Markers, Biochemical,Markers, Biological,Markers, Clinical,Markers, Immunologic,Markers, Laboratory,Markers, Serum,Markers, Surrogate,Markers, Viral,Serum Markers,Surrogate Markers,Viral Markers,Biochemical Marker,Biologic Marker,Biologic Markers,Clinical Marker,Immune Marker,Immune Markers,Immunologic Marker,Laboratory Marker,Marker, Biochemical,Marker, Biological,Marker, Clinical,Marker, Immunologic,Marker, Laboratory,Marker, Serum,Marker, Surrogate,Serum Marker,Surrogate End Point,Surrogate End Points,Surrogate Endpoint,Surrogate Endpoints,Surrogate Marker,Viral Marker,Biological Marker,End Point, Surrogate,End Points, Surrogate,Endpoint, Surrogate,Endpoints, Surrogate,Marker, Biologic,Marker, Immune,Marker, Viral,Markers, Biologic,Markers, Immune

Related Publications

J Tomás Gilabert, and M I Galán Navarro, and T Caballero Morales, and M C Maroto Vela, and A Ruiz Extremera, and F J Salmerón Escobar
February 1990, Liver,
J Tomás Gilabert, and M I Galán Navarro, and T Caballero Morales, and M C Maroto Vela, and A Ruiz Extremera, and F J Salmerón Escobar
October 1986, Klinicheskaia meditsina,
J Tomás Gilabert, and M I Galán Navarro, and T Caballero Morales, and M C Maroto Vela, and A Ruiz Extremera, and F J Salmerón Escobar
January 1980, Acta medica Academiae Scientiarum Hungaricae,
J Tomás Gilabert, and M I Galán Navarro, and T Caballero Morales, and M C Maroto Vela, and A Ruiz Extremera, and F J Salmerón Escobar
February 1985, Digestive diseases and sciences,
J Tomás Gilabert, and M I Galán Navarro, and T Caballero Morales, and M C Maroto Vela, and A Ruiz Extremera, and F J Salmerón Escobar
July 2002, Journal of viral hepatitis,
J Tomás Gilabert, and M I Galán Navarro, and T Caballero Morales, and M C Maroto Vela, and A Ruiz Extremera, and F J Salmerón Escobar
March 1990, Klinicheskaia meditsina,
J Tomás Gilabert, and M I Galán Navarro, and T Caballero Morales, and M C Maroto Vela, and A Ruiz Extremera, and F J Salmerón Escobar
January 1985, Hepatology (Baltimore, Md.),
J Tomás Gilabert, and M I Galán Navarro, and T Caballero Morales, and M C Maroto Vela, and A Ruiz Extremera, and F J Salmerón Escobar
July 1981, The New England journal of medicine,
J Tomás Gilabert, and M I Galán Navarro, and T Caballero Morales, and M C Maroto Vela, and A Ruiz Extremera, and F J Salmerón Escobar
January 1975, Rivista di emoterapia ed immunoematologia,
J Tomás Gilabert, and M I Galán Navarro, and T Caballero Morales, and M C Maroto Vela, and A Ruiz Extremera, and F J Salmerón Escobar
September 1991, Hepatology (Baltimore, Md.),
Copied contents to your clipboard!